You are viewing the site in preview mode

Skip to main content

Advertisement

Table 3 Baseline characteristics of included smear-negative presumptive TB patients who had a negative Xpert® MTB/RIF result by actual empirical TB treatment initiation

From: Treatment decisions and mortality in HIV-positive presumptive smear-negative TB in the Xpert® MTB/RIF era: a cohort study

Characteristic   Post-XP empirical Rx No post-XP empirical Rx Total P-value
Total (n [%])   22 130 152  
Age (mean [SD])   36 (12) 41 (11) 40 (10) 0.04
Female sex (n [%])   13 (59.1) 71 (54.6) 84 (55.3) 0.70
CD4 count (median [IQR])*   239 (139, 329) 289 (133, 456) 283 (133, 441) 0.25
ART at presentation   12 (54.5) 69 (53.1) 81 (53.3) 0.90
Prior TB treatment (n [%])   1 (4.5) 25 (19.2) 26 (17.1) 0.09
Symptomatology at presentation (n [%]) Cough 21 (95.5) 129 (99.2) 150 (98.7) 0.15
Fever 16 (72.7) 91 (70) 107 (70.4) 0.80
Night sweats 11 (50) 61 (46.9) 72 (47.4) 0.79
Weight loss 10 (45.5) 38 (29.2) 48 (31.6) 0.13
Anorexia 13 (59.1) 55 (42.3) 68 (44.7) 0.14
Chest pain 8 (36.4) 42 (32.3) 50 (32.9) 0.70
  1. IQR interquartile range, n number, Rx treatment, SD standard deviation, TB tuberculosis, XP Xpert® MTB/RIF
  2. *On 17, 118 and 135 patients, respectively